Quote Request
Pancreatic Cancer Metastatic Cell Model
The pancreatic cancer metastatic cell model is an important research tool designed to study the complex behavior of pancreatic cancer cells as they spread to other body parts. Alfa Cytology uses PC-related expertise and cutting-edge technology to develop highly repeatable and reliable pancreatic cancer metastatic cell models.
Overview of Pancreatic Cancer Metastatic Cell Model
Given the aggressive nature of pancreatic cancer and its tendency to metastasize early, the metastatic cell model provides valuable insights into the underlying mechanisms of tumor progression and spread. Human pancreatic cancer cell lines simulating the metastasis process commonly study cell characteristics such as migration, invasion, and response to therapeutic agents. The model could explore how metastatic pancreatic cancer cells evade the immune response and establish secondary tumors by simulating the tumor microenvironment and examining interactions with surrounding stromal cells.
Fig. 1 Stages of Metastatic Progression with candidate genes responsible per each stage. (Miquel M., et al., 2021)
In addition, the metastatic cell model can serve as a platform for testing new therapies, including targeted drugs and combination therapies. By evaluating the effectiveness of these interventions in a controlled setting, promising drug candidates can be identified for clinical trials. As a result, pancreatic cancer metastatic cell models are integral to uncovering the complexities of metastatic behavior, paving the way for more effective therapy development and improving the prognosis of this terrible disease.
Our Services
The metastatic cell model established for pancreatic cancer is important for understanding the mechanism of metastasis and improving therapy strategies. Alfa Cytology has been working to develop state-of-the-art models of Metastatic pancreatic cancer cells.
Common Cell Line Models for Pancreatic Cancer
Metastatic cell models typically use human pancreatic cancer cell lines to reflect the tumor heterogeneity better.
- Mia-PaCa-2
- AsPC-1
- HPAC
- PANC-1
- BxPC-3
- Hs776T
- CAPAN-1
- CAPAN-1
- PSN1
Development Process of Pancreatic Cancer Metastatic Cell Model
Select the Appropriate Cell Line
It mimics the metastatic behavior observed in pancreatic cancer.
Culture Cell
Matrix or collagen matrix is often used to better simulate the tumor microenvironment.
Interaction Detection
Interactions between cancer cells and surrounding stromal components, including fibroblasts and immune cells.
Assessing Migration and Invasion Capacity
Transwell assays, live cell imaging technology, and co-culture systems.
Repeated Testing and Validation
Screening potential therapeutic agents and identifying molecular pathways involved in metastasis to guide the development of more effective treatments for pancreatic cancer.
Why Choose Us?
Scientific Experience
Professional team of scientists and more than ten years of experience in pancreatic cancer
Customized Service
Tailored services dedicated to ensuring customer satisfaction
Data Security
Strictly keep confidential the client's project information and experimental data
Quick Reply
Our customer service representatives are available 24 hours a day from Monday to Sunday
Case Study - The HPAF-II Xenograft Model
- Model Introduction
The HPAF-II human pancreatic cancer cell line, established from the ascitic fluid of a patient with metastatic pancreatic ductal adenocarcinoma (PDAC), serves as a premier model for studying pancreatic cancer metastasis, particularly to the liver. Characterized by its epithelial origin, mutant KRAS and p53 status, and high metastatic potential, HPAF-II is an indispensable tool for preclinical research on invasion, metastasis, organ-specific colonization, and therapeutic response in advanced disease.
- Model Information
- Origin: Human ascitic fluid from a pancreatic ductal adenocarcinoma patient with liver metastasis.
- Classification: Pancreatic ductal adenocarcinoma (PDAC) cell line, mucinous subtype.
- Genetic Background: Harbors mutant KRAS and TP53 genes, consistent with human PDAC.
- Morphology: Epithelial-like.
- Growth Pattern: Adherent.
- Key Markers: Expresses epithelial markers (e.g., E-cadherin) and mucins; used in studies of metastatic progression and epithelial plasticity.
- Cancer Type: Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC)
- Model Validation (In Vivo)
The in vivo tumorigenicity and therapeutic response of the HPAF-II cell line were validated using a subcutaneous xenograft model. Tumors reached 100-200 mm3 by day 7 post-inoculation and progressed to the endpoint volume of 2000 mm3 by day 31. At the therapeutic intervention window (day 24), the control group showed an average tumor volume of 2090.7 mm3. Treatment with single doses of ADC drug A (11 mg/kg) and drug B (10 mg/kg) reduced tumor volumes to 1274.5 mm3 and 535.4 mm3, corresponding to tumor growth inhibition (TGI) rates of 39.0% and 74.4%, respectively. Both drugs A and B showed significant anti-tumor efficacy (p = 0.001).
Fig. 2 Tumor volume growth curve and body weight change in mice with subcutaneous HPAF-II pancreatic cancer cell xenografts (n=5). Data are presented as mean ± standard error (SEM). (Source: Alfa Cytology)
Alfa Cytology is a leader in cancer cell modeling and translational research, dedicated to advancing the understanding and therapy of cancer through innovative and cutting-edge technologies. Our multidisciplinary team of experts, state-of-the-art facilities, and commitment to excellence enable us to provide reliable, repeatable, and high-quality metastatic tumor models for a wide range of research applications. If you are interested in our services, please contact us for more details. You can contact our staff directly and receive professional, reliable, and fast feedback.
Reference
- Miquel M, et al. Pre-clinical Models of Metastasis in Pancreatic Cancer. Front Cell Dev Biol. 2021;9:748631. Published 2021 Oct 27. doi:10.3389/fcell.2021.748631
